Endocarditis caused by resistant enterococcus: An overview

Current Infectious Disease Reports

Volumn 15, Issue 4, 2013, Pages 320-328

  Reyes, Katherine ^a   Zervos, Marcus ^a,b  

^a Henry Ford Health System Division of Infectious Diseases   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Infective endocarditis; Multidrug resistant enterococci; VRE

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFTAROLINE; CEFTRIAXONE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; IMIPENEM; LINEZOLID; ORITAVANCIN; POLYPEPTIDE ANTIBIOTIC AGENT; STREPTOGRAMIN DERIVATIVE; SULTAMICILLIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ADD ON THERAPY; ANTIBIOTIC RESISTANCE; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; BLOODSTREAM INFECTION; CLINICAL EVALUATION; DRUG CHOICE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; INFECTION RISK; KIDNEY FUNCTION; LOW DRUG DOSE; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; SIDE EFFECT;

EID: 84880775447     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-013-0348-y     Document Type: Review

References (84)

1. Arias CA, Murray BE. Emergence and management of drug-resistant enterococcal infections. Expert Rev Anti Infect Ther. 2008;6(5):637-55.
2. • Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther. 2013;11(3):297-308. This paper lists Enterococcus faecium as one of the pathogens that may have new patterns of pathogenesis, transmission, and resistance.
3. Molton JS, Tambyah PA, Ang BS, et al. The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia. Clin Infect Dis. 2013;56(9):1310-8.
4. Fernández-Hidalgo N, Almirante B, Tornos P, et al. Contemporary epidemiology and prognosis of health care-associated infective endocarditis. Clin Infect Dis. 2008;47(10):1287-97.
5. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008;29(11):996-1011.
6. •• Chirouze C, Athan E, Alla F, et al. Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on Endocarditis-Prospective Cohort Study. Clin Microbiol Infect. 2013, Epub ahead of print. This is a multicenter prospective observational cohort study of 4,947 patients with endocarditis, 500 of which had enterococcal endocarditis.
7. Fernández Guerrero ML, Goyenechea A, Verdejo C, et al. Enterococcal endocarditis on native and prosthetic valves: a review of clinical and prognostic factors with emphasis on hospital-acquired infections as a major determinant of outcome. Medicine (Baltimore). 2007;86(6):363-77.
8. Olaison L, Schadewitz K. Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used? Clin Infect Dis. 2002;34(2):159-66.
9. McDonald JR, Olaison L, Anderson DJ, et al. Enterococcal endocarditis: 107 cases from the international collaboration on endocarditis merged database. Am J Med. 2005;118(7):759-66.
10. • Munita JM, Arias CA, Murray BE. Enterococcal endocarditis: can we win the war? Curr Infect Dis Rep. 2012;14(4):339-49. Comprehensive review of the pathogenesis and resistance mechanisms of enterococci and therapeutic options.
11. Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2008;32 Suppl 2:S133-45.
12. Reyes K, Malik R, Moore C, et al. Evaluation of risk factors for coinfection or cocolonization with vancomycin-resistant enterococcus and methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2010;48(2):628-30.
13. Pan SC, Wang JT, Chen YC, et al. Incidence of and risk factors for infection or colonization of vancomycin-resistant enterococci in patients in the intensive care unit. PLoS One. 2012;7(10):e47297.
14. Warren DK, Kollef MH, Seiler SM, et al. The epidemiology of vancomycin-resistant Enterococcus colonization in a medical intensive care unit. Infect Control Hosp Epidemiol. 2003;24(4):257-63.
15. Billström H, Lund B, Sullivan A, et al. Virulence and antimicrobial resistance in clinical Enterococcus faecium. Int J Antimicrob Agents. 2008;32(5):374-7.
16. Vergis EN, Shankar N, Chow JW, et al. Association between the presence of enterococcal virulence factors gelatinase, hemolysin, and enterococcal surface protein and mortality among patients with bacteremia due to Enterococcus faecalis. Clin Infect Dis. 2002;35(5):570-5.
17. Patterson JE, Zervos MJ. High-level gentamicin resistance in Enterococcus: microbiology, genetic basis, and epidemiology. Rev Infect Dis. 1990;12(4):644-52.
18. Alam MR, Donabedian S, Brown W, et al. Heteroresistance to vancomycin in Enterococcus faecium. J Clin Microbiol. 2001;39(9):3379-81.
19. Murray BE. Problems and perils of vancomycin resistant enterococci. Braz J Infect Dis. 2000;4(1):9-14.
20. Song JY, Cheong HJ, Seo YB, et al. Clinical and microbiological characteristics of vancomycin-resistant enterococci with the VanD phenotype and vanA genotype. Jpn J Infect Dis. 2013;66(1):1-5.
21. Al-Ahdal MN, Abozaid SM, Al-Shammary HF, et al. Characterization of Enterococcus faecium isolates and first report of vanB phenotype-vanA genotype incongruence in the Middle East. Eur J Clin Microbiol Infect Dis. 2012;31(11):3223-9.
22. Flamm RK, Mendes RE, Ross JE, et al. Linezolid surveillance results for the United States: LEADER surveillance program 2011. Antimicrob Agents Chemother. 2012;57(2):1077-81.
23. Hershberger E, Donabedian S, Konstantinou K, et al. Quinupristin- dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis. 2004;38(1):92-8.
24. Storm JC, Diekema DJ, Kroeger JS, et al. Daptomycin exposure precedes infection and/or colonization with daptomycin non-susceptible enterococcus. Antimicrob Resist Infect Control. 2012;1(1):19.
25. Arias CA, Torres HA, Singh KV, et al. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis. 2007;45(10):1343-6.
26. • Munita JM, Tran TT, Diaz L. A liaF Codon Deletion Abolishes Daptomycin Bactericidal Activity Against Vancomycin-Resistant Enterococcus faecalis. Antimicrob Agents Chemother. 2013, Epub ahead of print. This paper provides a direct correlation between gene mutation and tolerance of enterococci to daptomycin.
27. Johansson D, Rasmussen M. Virulence factors in isolates of Enterococcus faecalis from infective endocarditis and from the normal flora. Microb Pathog. 2013;55:28-31.
28. Anderson DJ, Murdoch DR, Sexton DJ, et al. Risk factors for infective endocarditis in patients with enterococcal bacteremia: a case-control study. Infection. 2004;32(2):72-7.
29. Forrest GN, Arnold RS, Gammie JS, et al. Single center experience of a vancomycin resistant enterococcal endocarditis cohort. J Infect. 2011;63(6):420-8.
30. McCracken M, Wong A, Mitchell R, et al. Molecular epidemiology of vancomycin-resistant enterococcal bacteraemia: results from the Canadian Nosocomial Infection Surveillance Program, 1999-2009. J Antimicrob Chemother. 2013, Epub ahead of print.
31. McKinnell JA, Patel M, Shirley RM, et al. Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents. Epidemiol Infect. 2011;139:1342-50.
32. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Song, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005;111:e394-434.
33. Monkowski DH, Axelrod P, Fekete T, et al. Infections associated with ventricular assist devices: epidemiology and effect on prognosis after transplantation. Transpl Infect Dis. 2007;9(2):114-20.
34. Arias CA, Mendes RE, Stilwell MG, et al. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections. Clin Infect Dis. 2012;54 Suppl 3:S233-8.
35. Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol. 2003;24:690-8.
36. Mikulska M, Del Bono V, Raiola AM, et al. Enterococcal bloodstream infection after hematopoietic stem cell transplant: experience of a center with a low prevalence of vancomycin-resistant enterococci. Clin Infect Dis. 2012;55(12):1744.
37. Stevens MP, Edmond MB. Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature. Clin Infect Dis. 2005;41(8):1134-42.
38. Wilson WR, Wilkowske CJ, Wright AJ, et al. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. Ann Intern Med. 1984;100(6):816-23.
39. Casalta JP, Thuny F, Fournier PE, et al. DNA persistence and relapses questions on the treatment strategies of Enterococcus infections of prosthetic valves. PLoS One. 2012;7(12):e53335.
40. •• Fernández-Hidalgo N, Almirante B, Gavaldà J, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin Infect Dis. 2013;56(9):1261-8. This is a nonrandomized, observational, multicenter study that evaluated the combination of ampicillin plus ceftriaxone to treat E. faecalis endocarditis against a control group that received the combination of ampicillin and aminoglycoside.
41. Gavaldà J, Len O, Miró JM, et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med. 2007;146:574-9.
42. Tascini C, Doria R, Leonildi A, et al. Efficacy of the combination ampicillin plus ceftriaxone in the treatment of a case of enterococcal endocarditis due to Enterococcus faecalis highly resistant to gentamicin: efficacy of the "ex vivo" synergism method. J Chemother. 2004;16(4):400-3.
43. Miro JM, Cervera C, Garcia-de-la-Maria C, et al. Success of ampicillin plus ceftriaxone rescue therapy for a relapse of Enterococcus faecalis native-valve endocarditis and in vitro data on double beta-lactam activity. Scand J Infect Dis. 2008;40(11-12):968-72.
44. Gavaldá J, Onrubia PL, Gómez MT, et al. Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides. J Antimicrob Chemother. 2003;52(3):514-7.
45. Gavaldà J, Torres C, Tenorio C, et al. Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides. Antimicrob Agents Chemother. 1999;43(3):639-46.
46. Sierra-Hoffman M, Iznaola O, Goodwin M, et al. Combination therapy with ampicillin and daptomycin for treatment of Enterococcus faecalis endocarditis. Antimicrob Agents Chemother. 2012;56(11):6064.
47. Brandt CM, Rouse MS, Laue NW, et al. Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents. J Infect Dis. 1996;173(4):909-13.
48. Thauvin C, Eliopoulos GM, Willey S, et al. Continuous infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother. 1987;31:139-43.
49. Mekonen ET, Noskin GA, Hacek DM, et al. Succesful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium. Microb Drug Resist. 1995;1:249-53.
50. Pérez Salmerón J, Martínez García F, Roldán Conesa D, et al. Comparative study of treatment with quinupristin-dalfopristin alone or in combination with gentamicin, teicoplanin, imipenem or levofloxacin in experimental endocarditis due to a multidrug-resistant Enterococcus faecium. Rev Esp Quimioter. 2006;19(3):258-66. Spanish.
51. Bethea JA, Walko CM, Targos PA. Treatment of vancomycin-resistant enterococcus with quinupristin/dalfopristin and high-dose ampicillin. Ann Pharmacother. 2004;38(6):989-91.
52. Thompson RL, Lavin B, Talbot GH. Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: cure by administering combination therapy with quinupristin/dalfopristin and high-dose ampicillin. South Med J. 2003;96(8):818-20.
53. Bostic GD, Perri MB, Thal LA, et al. Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci. Diagn Microbiol Infect Dis. 1998;30(2):109-12.
54. Noskin GA, Siddiqui F, Stosor V, et al. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin. Clin Infect Dis. 1999;28(3):689-90.
55. Wareham DW, Abbas H, Karcher AM, et al. Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid. J Infect. 2006;52(4):300-4.
56. Crank CW, Scheetz MH, Brielmaier B, et al. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: a retrospective, multicenter, cohort study. Clin Ther. 2010;32(10):1713-9.
57. Lauridsen TK, Bruun LE, Rasmussen RV, et al. Linezolid as rescue treatment for left-sided infective endocarditis: an observational, retrospective, multicenter study. Eur J Clin Microbiol Infect Dis. 2012;31(10):2567-74.
58. Eliopoulos GM. Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria. J Infect. 2009;59 Suppl 1:S17-24.
59. Schutt AC, Bohm NM. Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin. Ann Pharmacother. 2009;43(12):2108-12.
60. Polidori M, Nuccorini A, Tascini C, et al. Vancomycin-resistant Enterococcus faecium (VRE) bacteremia in infective endocarditis successfully treated with combination daptomycin and tigecycline. J Chemother. 2011;23(4):240-1.
61. Kullar R, Davis SL, Levine DP, et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy. 2011;31(6):527-36.
62. Kelesidis T, Humphries R, Uslan DZ, et al. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis. 2011;52(2):228-34.
63. Enoch DA, Phillimore N, Karas JA, et al. Relapse of enterococcal prosthetic valve endocarditis with aortic root abscess following treatment with daptomycin in a patient not fit for surgery. J Med Microbiol. 2010;59(Pt 4):482-5.
64. Kanafani ZA, Federspiel JJ, Fowler Jr VG. Infective endocarditis caused by daptomycin-resistant Enterococcus faecalis: a case report. Scand J Infect Dis. 2007;39(1):75-7.
65. • Sakoulas G, Bayer AS, Pogliano J, et al. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 2011;56(2):838-44. This paper demonstrated synergy between ampicillin and daptomycin in treating a patient with endocarditis due to Enterococcus faecium resistant to vancomycin and ampicillin.
66. Hall AD, Steed ME, Arias CA, et al. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2012;56(6):3174-80.
67. Chitnis S, Katara G, Hemvani N, et al. In vitro activity of daptomycin & linezolid against methicillin resistant Staphylococcus aureus & vancomycin resistant enterococci isolated from hospitalized cases in Central India. Indian J Med Res. 2013;137(1):191-6.
68. Giannakaki V, Miyakis S. Novel antimicrobial agents against multi-drug-resistant gram-positive bacteria: an overview. Recent Pat Antiinfect Drug Discov. 2012;7(3):182-8.
69. Hope R, Chaudhry A, Adkin R, et al. In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci. Int J Antimicrob Agents. 2013;41(3):213-7.
70. Morrissey I, Seifert H, Canton R, et al. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011. J Antimicrob Chemother. 2013;68(1):164-7.
71. Jacqueline C, Caillon J, Le Mabecque V, et al. In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and vancomycin. Antimicrob Agents Chemother. 2009;53(12):5300-2.
72. Pavleas J, Skiada A, Daikos GL, et al. Efficacy of teicoplanin, administered in two different regimens, in the treatment of experimental endocarditis due to Enterococcus faecalis. J Chemother. 2008;20(2):208-12.
73. Munita JM, Arias CA, Murray BE. Enterococcus faecalis infective endocarditis: is it time to abandon aminoglycosides? Clin Infect Dis. 2013;56(9):1269-72.
74. Araoka H, Kimura M, Yoneyama A. A surveillance of high-level gentamicin-resistant enterococcal bacteremia. J Infect Chemother. 2011;17(3):433-4.
75. Dubé L, Caillon J, Jacqueline C. The optimal aminoglycoside and its dosage for the treatment of severe Enterococcus faecalis infection. An experimental study in the rabbit endocarditis model. Eur J Clin Microbiol Infect Dis. 2012;31(10):2545-7.
76. Tripathi A, Shukla SK, Singh A, et al. A new approach of real time polymerase chain reaction in detection of vancomycin-resistant enterococci and its comparison with other methods. Indian J Med Microbiol. 2013;31(1):47-52.
77. Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. A prospective multicenter study. Ann Intern Med. 2001;135:484-92.
78. Cheah AL, Spelman T, Liew D, et al. Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization. Clin Microbiol Infect. 2013;19(4):E181-9.
79. Sohn KM, Peck KR, Joo EJ, et al. Duration of colonization and risk factors for prolonged carriage of vancomycin-resistant enterococci after discharge from the hospital. Int J Infect Dis. 2013;17(4):e240-6.
80. Mutters NT, Brooke RJ, Frank U, et al. Low risk of apparent transmission of vancomycin-resistant Enterococci from bacteraemic patients to hospitalized contacts. Am J Infect Control. 2013, Epub ahead of print.
81. Friedman ND, Walton AL, Boyd S, et al. The effectiveness of a single-stage versus traditional three-staged protocol of hospital disinfection at eradicating vancomycin-resistant Enterococci from frequently touched surfaces. Am J Infect Control. 2013;41(3):227-31.
82. Bass P, Karki S, Rhodes D, et al. Impact of chlorhexidine-impregnated washcloths on reducing incidence of vancomycin-resistant enterococci colonization in hematology-oncology patients. Am J Infect Control. 2013;41(4):345-8.
83. Varela AR, Ferro G, Vredenburg J, et al. Vancomycin resistant enterococci: from the hospital effluent to the urban wastewater treatment plant. Sci Total Environ. 2013;450-451:155-61.
84. Gordoncillo MJ, Donabedian S, Bartlett PC, et al. Isolation and Molecular Characterization of Vancomycin-Resistant Enterococcus faecium from Swine in Michigan, USA. Zoonoses Public Health. 2012, Epub ahead of print.